News headlines about Lion Biotechnologies (NASDAQ:IOVA) have been trending somewhat positive this week, according to Accern. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lion Biotechnologies earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.5428511013476 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several analysts recently weighed in on the company. Chardan Capital restated a “buy” rating on shares of Lion Biotechnologies in a research note on Thursday, September 7th. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. Oppenheimer Holdings, Inc. set a $13.00 target price on Lion Biotechnologies and gave the company a “buy” rating in a research note on Friday, August 18th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a research note on Wednesday, August 16th. Finally, Zacks Investment Research downgraded Lion Biotechnologies from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $13.88.

Shares of Lion Biotechnologies (NASDAQ IOVA) traded down 2.52% during mid-day trading on Friday, hitting $7.75. The company’s stock had a trading volume of 204,991 shares. Lion Biotechnologies has a 1-year low of $4.45 and a 1-year high of $8.60. The company’s market cap is $554.33 million. The company has a 50-day moving average of $5.61 and a 200 day moving average of $6.42.

COPYRIGHT VIOLATION WARNING: “Lion Biotechnologies (IOVA) Receiving Somewhat Favorable News Coverage, Report Finds” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/06/lion-biotechnologies-iova-receiving-somewhat-favorable-news-coverage-report-finds.html.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Insider Buying and Selling by Quarter for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.